REPL
Replimune Group, Inc. · Healthcare
Insiders sold $1.8M of Replimune Group, Inc. in the last 12 months and bought none
REPL over the last year
REPL after insider buys
3 months after each buy, from the first price a copier could get.
No buys have 3 months of prices yet. A record shows here at 3.
Every filing
114 insider filings since 2018, newest first
Emily Luisa Hill · Chief Financial Officer
Sushil Patel · Chief Executive Officer
Emily Luisa Hill · Chief Financial Officer
Konstantinos Xynos · Chief Medical Officer
Andrew Schwendenman · Chief Accounting Officer
Christopher Sarchi · Chief Commercial Officer
Konstantinos Xynos · Chief Medical Officer
Andrew Schwendenman · Chief Accounting Officer
Christopher Sarchi · Chief Commercial Officer
Philip Astley-Sparke · Director
Sushil Patel · Chief Executive Officer
Emily Luisa Hill · Chief Financial Officer
Christopher Sarchi · Chief Commercial Officer
Kapil Dhingra · Director
Sushil Patel · CEO
Konstantinos Xynos · Chief Medical Officer
Christopher Sarchi · Chief Commercial Officer
Emily Luisa Hill · CFO
Konstantinos Xynos · Chief Medical Officer
Philip Astley-Sparke · Executive Chair
Sushil Patel · CEO
Konstantinos Xynos · Chief Medical Officer
Colin Love · COO
Robert Coffin · Director
Konstantinos Xynos · Chief Medical Officer
Christopher Sarchi · Chief Commercial Officer
Pamela Esposito · Chief Business Officer
Pamela Esposito · Chief Business Officer
Pamela Esposito · Chief Business Officer
Pamela Esposito · Chief Business Officer
Sushil Patel · Chief Strategy Officer
Tanya Lewis · Chief Dev. Op. Officer
Sushil Patel · Chief Strategy Officer
Jean M. Franchi · CFO
Philip Astley-Sparke · CEO
Robert Coffin · Pres, Chief R, D Officer
Tanya Lewis · Chief Dev. Op. Officer
Colin Love · COO
Pamela Esposito · Chief Business Officer
Pamela Esposito · Chief Business Officer
Jean M. Franchi · CFO
Sushil Patel · Chief Commercial Officer
Philip Astley-Sparke · CEO
Colin Love · COO
Pamela Esposito · Chief Business Officer
Tanya Lewis · Chief Dev. Op Officer
Robert Coffin · Pres, Chief R, D Officer
Omega Fund Iv, L.P. · 10% owner
Omega Fund Iv, L.P. · Director and 10% owner
Omega Fund Iv, L.P. · Director and 10% owner
About Replimune Group, Inc.
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3, which express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Filings come from SEC EDGAR and prices from daily closes. Not investment advice.